Avanir Pharmaceuticals announced that it will terminate the license agreement with Optinose for intranasal migraine medication ONZETRA Xsail (sumatriptan nasal powder). Optinose, of Yardley, Pa., is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Avanir will coordinate closely with Optinose during the transition period.
"Avanir's decision to terminate its license agreement with Optinose for ONZETRA® Xsail® will help us intensify our strategic focus on developing innovative central nervous system solutions to improve the lives of patients and their care communities," said Wa'el Hashad, Chief Executive Officer of Avanir. "From developing treatments for agitation in Alzheimer's dementia, disinhibition in traumatic brain injury, and the negative symptoms of schizophrenia, our research pipeline is focused on and dedicated to creating a future of hope and promise by addressing unmet needs that arise as a result of central nervous system disorders."